Literature DB >> 5309486

Adjuvant influenza vaccines.

C H Stuart-Harris.   

Abstract

Emulsified inactivated influenza vaccines have been in use for some 18 years and the goal of enhanced serological response lasting 2 years or more has been attained. The safety of the method in relation to immediate pyrogenic reactions has been demonstrated and no carcinogenic effects are known to have occurred in man. However, the problem of delayed local reactions after the injection of mineral-oil vaccines has not been solved. British experience of adverse reactions to commercial adjuvant influenza vaccine is quoted.New methods for obtaining adjuvant action without the risk of local abscess formation are needed both for inactivated whole virus and for split haemagglutinin vaccines. Reversal of water-in-mineral-oil emulsion to oil-in-water emulsion reduces viscosity and permits diffusion of the depot injection. A trial in Britain has shown equally good adjuvant properties of the reversed emulsion incorporating influenza virus vaccine so far as serological response is concerned, although it has not yet been conducted on a scale that would allow of adequate evaluation of the likelihood of delayed local reactions.

Entities:  

Mesh:

Substances:

Year:  1969        PMID: 5309486      PMCID: PMC2427695     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  13 in total

1.  NEW METABOLIZABLE IMMUNOLOGIC ADJUVANT FOR HUMAN USE. I. DEVELOPMENT AND ANIMAL IMMUNE RESPONSE.

Authors:  A F WOODHOUR; D P METZGAR; T B STIM; A A TYTELL; M R HILLEMAN
Journal:  Proc Soc Exp Biol Med       Date:  1964-06

2.  STIMULATION OF ISOHEMOLYSINS AND ISOHEMAGGLUTININS BY INFLUENZA VIRUS PREPARATIONS.

Authors:  G F SPRINGER; R SCHUSTER
Journal:  Vox Sang       Date:  1964 Sep-Oct       Impact factor: 2.144

3.  FOLLOW-UP STUDY ON ARMY PERSONNEL WHO RECEIVED ADJUVANT INFLUENZA VIRUS VACCINE 1951-1953.

Authors:  G W BEEBE; A H SIMON; S VIVONA
Journal:  Am J Med Sci       Date:  1964-04       Impact factor: 2.378

4.  Blood group A active substances in embryonated chicken eggs and their relation to egggrown virus.

Authors:  G F SPRINGER; H TRITEL
Journal:  Science       Date:  1962-11-09       Impact factor: 47.728

5.  Ascites production in 17 mouse strains.

Authors:  R LIEBERMAN; N MANTEL; W HUMPHREY
Journal:  Proc Soc Exp Biol Med       Date:  1961-05

6.  Seventeen years' experience with mineral oil adjuvant influenza virus vaccines.

Authors:  F M Davenport
Journal:  Ann Allergy       Date:  1968-06

7.  Antibody response and reactions to aqueous influenza vaccine, simple emulsion vaccine and multiple emulsion vaccine. A report to the Medical Research Council Committee on influenza and other respiratory virus vaccines.

Authors:  P J Taylor; C L Miller; T M Pollock; F T Perkins; M A Westwood
Journal:  J Hyg (Lond)       Date:  1969-09

8.  Reticular neoplasms induced in DBA-2 and CBA mice by intraperitoneal injections of mineral oil.

Authors:  R Rask-Nielsen; P Ebbesen
Journal:  J Natl Cancer Inst       Date:  1965-07       Impact factor: 13.506

9.  Lack of adjuvant effect of A1PO4 on purified influenza virus hemagglutinins in man.

Authors:  F M Davenport; A V Hennessy; F B Askin
Journal:  J Immunol       Date:  1968-05       Impact factor: 5.422

10.  Multiple emulsions. A new form of mineral-oil antigen adjuvant.

Authors:  W J Herbert
Journal:  Lancet       Date:  1965-10-16       Impact factor: 79.321

View more
  13 in total

Review 1.  The development and use of vaccine adjuvants.

Authors:  Robert Edelman
Journal:  Mol Biotechnol       Date:  2002-06       Impact factor: 2.695

2.  Response to influenza vaccine in adjuvant 65-4.

Authors:  J W Smith; W B Fletcher; M Peters; M Westwood; F J Perkins
Journal:  J Hyg (Lond)       Date:  1975-04

Review 3.  Continuing challenges in influenza.

Authors:  Robert G Webster; Elena A Govorkova
Journal:  Ann N Y Acad Sci       Date:  2014-05-30       Impact factor: 5.691

4.  The search for the ideal influenza vaccine.

Authors:  F M Davenport
Journal:  Postgrad Med J       Date:  1979-02       Impact factor: 2.401

5.  A TLR4-derived non-cytotoxic, self-assembling peptide functions as a vaccine adjuvant in mice.

Authors:  Anshika Tandon; Manisha Pathak; Munesh Kumar Harioudh; Sabahuddin Ahmad; Mohd Sayeed; Tayyaba Afshan; M I Siddiqi; Kalyan Mitra; Shailja M Bhattacharya; Jimut Kanti Ghosh
Journal:  J Biol Chem       Date:  2018-11-01       Impact factor: 5.157

6.  Adjuvant activity of a novel metabolizable lipid emulsion with inactivated viral vaccines.

Authors:  J A Reynolds; D G Harrington; C L Crabbs; C J Peters; N R Di Luzio
Journal:  Infect Immun       Date:  1980-06       Impact factor: 3.441

7.  Vaxjo: a web-based vaccine adjuvant database and its application for analysis of vaccine adjuvants and their uses in vaccine development.

Authors:  Samantha Sayers; Guerlain Ulysse; Zuoshuang Xiang; Yongqun He
Journal:  J Biomed Biotechnol       Date:  2012-03-13

Review 8.  Polyionic vaccine adjuvants: another look at aluminum salts and polyelectrolytes.

Authors:  Bradford S Powell; Alexander K Andrianov; Peter C Fusco
Journal:  Clin Exp Vaccine Res       Date:  2015-01-30

9.  Toxoplasma gondii Proteasome Subunit Alpha Type 1 with Chitosan: A Promising Alternative to Traditional Adjuvant.

Authors:  Zhengqing Yu; Wenxi Ding; Muhammad Tahir Aleem; Junzhi Su; Junlong Liu; Jianxun Luo; Ruofeng Yan; Lixin Xu; Xiaokai Song; Xiangrui Li
Journal:  Pharmaceutics       Date:  2021-05-19       Impact factor: 6.321

Review 10.  Influenza vaccines: unmet needs and recent developments.

Authors:  Ji Yun Noh; Woo Joo Kim
Journal:  Infect Chemother       Date:  2013-12-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.